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ABSTRACT Amphetamine is taken up through the dopamine transporter in nerve
terminals and enhances the release of dopamine. We previously found that incubation of
rat striatal synaptosomes increases phosphorylation of the presynaptic neural-specific
protein, neuromodulin (Gnegy et al., Mol. Brain Res. 20:289–293, 1993). Using a
state-specific antibody, we now demonstrate that incubation of rat striatal synaptosomes
with amphetamine increases levels of neuromodulin phosphorylated at ser41, the protein
kinase C substrate site. Phosphorylation wasmaximal at 5min at 37°C at concentrations
from 100 nM to 10 µM amphetamine. The effect of amphetamine on the phosphorylation
of synapsin I at a site specifically phosphorylated by Ca21/calmodulin-dependent protein
kinase II (site 3), was examined using a state-specific antibody for site 3-phosphosynap-
sin I. Incubation with concentrations of amphetamine from 1 to 100 nM increased the
level of site 3-phospho-synapsin I at times from 30 sec to 2 min. The effect of
amphetamine on synapsin I phosphorylation was blocked by nomifensine. The presence
of calcium in the incubating buffer was required for amphetamine to increase the level of
site 3-phospho-synapsin I. The amphetamine-mediated increase in the content of
phosphoser41-neuromodulinwas less sensitive to extrasynaptosomal calcium. The amphet-
amine-mediated increase in the content of site 3-phospho-synapsin I persisted in the
presence of 10 µM okadaic acid and was not significantly altered by D1 or D2 dopamine
receptor antagonists. Preincubation of striatal synaptosomes with 10 µM of the protein
kinase C inhibitor, Ro-31-8220, blocked the amphetamine-mediated increases in the
levels of both phosphoser41-neuromodulin and site 3-phospho-synapsin I. Our results
demonstrate that amphetamine can alter phosphorylation-related second messenger
activities in the synaptosome. Synapse 26:281–291, 1997. r 1997 Wiley-Liss, Inc.
INTRODUCTION
Amphetamine (AMPH) is a powerful psychostimu-
lant whose abuse is escalating in the United States
(Miller and Hughes, 1994). In humans and laboratory
animals, AMPH induces hyperkinesis and stereotyped
behaviors. AMPH increases locomotor and stereotyped
behaviors predominantly through enhanced release of
dopamine (DA) in the striatum and nucleus accumbens
(Segal and Kuczenski, 1994; Seiden et al., 1993). Up-
take through the DA transporter is critical for the
ability ofAMPH to release dopamine and elicit hyperac-
tive behavior (Giros et al., 1996; and see references in
Seiden et al., 1993). AMPH-induced DA release is
postulated to occur through an exchange-diffusion pro-
cess (Fischer and Cho, 1979; Liang and Rutledge,
1982). Depending upon the dose, AMPH can release DA
from both cytoplasmic and vesicular stores (see refer-
ences in Seiden et al., 1993). Although AMPH-induced
DA release is Ca21-independent (Raiteri et al., 1979;
Rutledge, 1978) there are AMPH-mediated activities
that appear to involve Ca21. Low concentrations of
AMPH stimulate DA synthesis in striatal synapto-
somes by a Ca21-dependent mechanism (Fung and
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Uretsky, 1982; Roberts and Patrick, 1979; Schwarz et
al., 1980; Uretsky and Snodgrass, 1977). In addition,
AMPH can increase protein kinase C activity in striatal
synaptoneurosomes through a decrease in the Km for
Ca21 (Giambalvo, 1992a,b).
We found that AMPH increased phosphorylation of
the neural-specific protein neuromodulin (NM; GAP-
43, B-50, F1) in rat striatum after acute intraperitoneal
injection and in striatal synaptosomes after incubation
(Gnegy et al., 1993; Iwata et al., 1996). NM binds
calmodulin (CaM), actin and Go and is important for
nerve growth, neurotransmitter release, and synaptic
plasticity (Coggins and Zwiers, 1991; Skene, 1989).
PKC-mediated phosphorylation of NM at ser41, which
adjoins the CaM-binding region (Coggins and Zwiers,
1989), results in the dissociation of bound CaM (Alex-
ander et al., 1987). The presence of phospho-ser41 on
NM appears to be important for the ability of NM to
positively modulate neurotransmitter release (Dekker
et al., 1989, 1990; Hens et al., 1995). We found an
increase in content of phosphoser41-NM in rat striatum
upon withdrawal from repeated, intermittent AMPH
(Iwata et al., 1996). Upon withdrawal from this regi-
men of repeated, intermittent AMPH, rats exhibit
behavioral sensitization to AMPH, as expressed by a
more rapid onset of stereotyped behaviors, more in-
tense stereotyped movements, and a marked increase
in AMPH-induced rotation (Robinson, 1991; for review,
see Robinson and Becker, 1986).An enhanced stimulus-
induced release of dopamine upon withdrawal has been
consistently measured in both striatum (Robinson and
Becker, 1982) and nucleus accumbens (Robinson et al.,
1988) of amphetamine sensitized animals. The phos-
phorylation state of another CaM-binding protein in-
volved in neurotransmitter release, synapsin I, was
also enhanced in striatum of rats treated with repeated,
intermittent AMPH (Iwata et al., 1996). Using a state-
specific antibody, we found that the phosphorylation
state of synapsin I at site 3 was increased after re-
peated AMPH. Site 3 is phosphorylated by Ca21/CaM-
dependent protein kinase II (CaM Kinase II) and
Ca21/CaM-dependent protein kinase IV. Synapsin I
binds to the cytosolic surface of synaptic vesicles and to
various cytoskeletal proteins such as F-actin, microtu-
bules, neurofilaments and spectrin (De Camilli et al.,
1990; Greengard et al., 1993; Valtorta et al., 1992).
Phosphorylation of the nerve terminal-specific synap-
sin I by CaM Kinase II at sites 2 and 3 decreases its
affinity for synaptic vesicles as well as for the cytoskel-
eton (De Camilli et al., 1990; Greengard et al., 1993;
Valtorta et al., 1992) which may affect the number of
vesicles available for release (Pieribone et al., 1995;
Rosahl et al., 1995). Although acute as well as repeated
AMPH increased NM phosphorylation in rat striatum,
acute AMPH did not increase the phosphorylation of
synapsin I (Iwata et al., 1996). Since AMPH was
injected 30min before striatum removal, a rapid AMPH-
induced phosphorylation/dephosphorylation of synap-
sin I would have been undetected.
The goal of this study was to further investigate the
AMPH-mediated phosphorylation of NM in synapto-
somes and determine whether AMPH can increase
CaM Kinase II activity as assessed by synapsin I
phosphorylation. We validated a site of AMPH-medi-
ated phosphorylation of NM as ser41 using a state-
dependent antibody. In addition, using the state-
dependent antibody for synapsin I, we found that
incubation of synaptosomes with AMPH increased the
content of site 3-phospho-synapsin I. Our results sug-
gest that AMPH can alter phosphorylation-related sec-
ond messenger activities in the synaptosome.
MATERIALS AND METHODS
Materials
d-AMPH sulfate was purchased from The University
of Michigan Laboratory of Animal Medicine. Nomifen-
sine was obtained from Hoechst (Frankfurt, Germany)
and dissolved in an aqueous solution at 4 mM with
lactic acid to lower the pH. Okadaic acid sodium salt
was purchased from LC Laboratory (Woburn, MA).
Sulpiride was obtained from the Laboratoire Etudes et
Developement Chimiques (Arpajon, France) and first
dissolved in dimethylsulfoxide to a concentration of 160
mM. SCH23390 maleate was obtained from Schering,
Co. (Bloomfield, NJ) and dissolved in dimethylsulfoxide
to a concentration of 40 mM. Ro31-8220 was obtained
from Calbiochem-Novabiochemicals (San Diego, CA)
and dissolved in dimethylsulfoxide to a concentration of
1.8 mM. 125I-protein A was purchased from Amersham
(Arlington Heights, IL). Myelin basic protein4–14 and
the protein kinase C inhibitor peptide were purchased
from Upstate Biochemicals (Lake Placid, NY).
[g-32P]ATP (spec. act. .4,000 Ci/mmol) was from ICN
(Irvine, CA). The state-dependent antibody for phos-
phoser41-NM (2G12/c7) was the generous gift of Dr.
Karina Meiri, Department of Pharmacology, SUNY
Health Science Center. The state-dependent antibody
for site 3-phospho-synapsin I (RU19) was generously
donated by Dr. Andrew Czernik, Laboratory of Molecu-
lar and Cellular Neuroscience, Rockefeller University.
Preparation of striatal synaptosomes
Synaptosomes were prepared as described by Dunk-
ley et al. (1986). Striata from female Holtzman rats
(Harlan Sprague Dawley, Inc., Indianapolis, IN) were
dissected using a brain cutting block (Heffner et al.,
1980). The striatum was homogenized in a glass-teflon
homogenizer in 10 vol of 0.32 M sucrose solution
containing 1.0 mM ethylenediaminetetraacetic acid
(EDTA), 0.25 mM dithiothreitol, 10 µM leupeptin, 10
µM pepstatin A, 1 mM phenylmethylsulfonyl fluoride
(PMSF), pH 7.4. The homogenate was centrifuged at
1,000g for 10 min, the pellet washed, and the combined
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supernatants were further centrifuged at 15,000g for
30 min. The P2 fraction was resuspended in 13 vol of
sucrose solution and layered on Percoll (Pharmacia
LKB Biotechnology, Piscataway, NJ) gradients, com-
prised of 2 ml each of 23, 15, 10, and 3% Percoll (v/v) in
sucrose solution. The gradient was centrifuged at
32,500g for 5 min without braking. Fraction 4 was
collected by aspiration and mixed with either Ca21-
deficient Krebs Ringer Buffer (KRB; 118 mM NaCl, 4.7
mM KCl, 1.2 mM MgCl2, 24.9 mM NaHCO3, 10 mM
glucose, brought to pH 7.4 by oxygenation) for synapsin
I measurement or Ca21-replete KRB containing 1.2 mM
CaCl2 for NMmeasurement. Synaptosomeswere centri-
fuged at 15,000g for 15 min. The final pellet was
resuspended in 4 vol of either Ca21-deficient KRB (for
synapsin I measurements) or Ca21-replete KRB (for
NM measurements) to give a protein concentration of
approximately 1.2 mg/ml. The effect ofAMPH on synap-
sin I phosphorylation was more consistent when synap-
tosomes were resuspended in Ca21-deficient KRB.
Synaptosome incubation
Phosphorylation assays were commenced by adding
Ca21-containing KRB (final Ca21 was 1.2 mM) with or
without various concentrations of AMPH to synapto-
somes for varying lengths of time at 37°C. Final incuba-
tion volume was 60 µl. The reaction was terminated
with 20 µl SDS-stop solution (final concentration: 52.5
mMTris/HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS),
10% glycerol, 5% 2-mercaptoethanol, 0.002% bromophe-
nol blue) and boiled at 100°C for 5 min. Nomifensine,
okadaic acid, sulpiride, Ro31-8220, and SCH23390
were diluted from stock in Ca21-free KRB. Synapto-
somes were preincubated with the drugs at 4°C for
20–60 min.
Immunoblotting
NM was separated by 10% SDS-PAGE (sodium do-
decyl sulfate polyacrylamide gel electrophoresis) and
transferred onto nitrocellulose paper using a Bio-Rad
minitransfer apparatus (Bio-Rad Laboratories, Her-
cules, CA) at 30 V for 14 h. Each lane contained 10–15
µg protein for measurement of phosphoser41-NM or 15
µg of protein for total NM. Blots were blocked in
Tris-buffered saline (10mMTris, 150mMNaCl, pH 7.4)
containing 0.1% Tween 20 and 1% bovine serum albu-
min (blocking buffer), then incubated for 1 h with a
monoclonal antibody (2G12/c7) (Meiri et al., 1991)
specific for phosphoser41-NM diluted 1:50 in blocking
buffer or with antibody for total NM (10E8/E7) (Meiri et
al., 1991) diluted 1:100 in blocking buffer. Blots were
then incubated for 1 h with anti-mouse IgG coupled to
alkaline phosphatase (Calbiochem-Novabiochem Co.,
San Diego, CA) diluted 1:20,000 in blocking buffer.
Immunoreactivity on the blots was also visualized with
ECL (enhanced chemiluminescence) purchased from
Amersham Co. (Arlington Heights, IL). Results were
analyzed by scanning the bands using aHoefer GS365W
scanning densitometer (Hoefer Scientific Instruments,
San Francisco, CA). The peak areas were quantified by
Gaussian integration usingHoefer GS365W electropho-
resis data system.
Synapsin I was separated by 7.5% SDS-PAGE and
transferred onto polyvinylidene difluoride membrane
(Immobilon P, Millipore Co., Bedford, MA) using a
Transphor electrophoresis unit (Hoefer Scientific Instru-
ments, San Francisco, CA) at 100 V for 1 h. For
measurement of site 3-phospho-synapsin I, each lane
contained 5–10 µg protein. Blots were incubated in
blocking buffer for 1 h, then incubated for 2 h with
antibody specific for site 3-phosphosynapsin I (RU19)
diluted 1:50. The synapsin I antibody was affinity-
purified rabbit polyclonal anti-peptide antibody (Cz-
ernik et al., 1991, 1995; Yamagata et al., 1995). In vitro,
phosphorylation of synapsin I by CaM Kinase II occurs
at an equivalent rate and to an equivalent stoichiom-
etry at sites 2 and 3. Using two phosphopeptides
corresponding to a distinct sequence surrounding each
site, RU19 was determined to be specific for site 3 of
synapsin I. Immunoreactivity on the blots was visual-
ized with 125I-protein A (2 mCi). Total radioactivity was
quantified by a Phosphor Imager (Molecular Dynamics,
Sunnyvale, CA), and densitometry values were ob-
tained. Immunoreactivity was also visualized using an
anti-rabbit IgG coupled to alkaline phosphatase (Gibco,
Gaithersburg, MD).
Measurement of protein kinase C activity
Synaptosomes were incubated with 1 µM amphet-
amine for 2 min. Two volumes of cold Ca21-deficient
KRB was added to the incubation; the synaptosomes
were pelleted and resuspended in a buffer consisting of
20 mM Tris HCl, pH 7.5, 10 µM leupeptin, and 1 mM
PMSF. A set of control and AMPH-incubated synapto-
somes were kept intact.After 15 min, the synaptosomes
were sonicated for 15 sec and centrifuged at 100,000g
for 60 min. The pellets were resuspended in a buffer
containing 20 mM Tris HCl, pH 7.5 containing 1%
Triton X-100, 10 µM leupeptin, and 1 mM PMSF. The
membrane protein was diluted over 10-fold into the
assay. Protein kinase C activity in non-lysed synapto-
somes, supernatants, and pellets was measured in an
assay (50 µl) containing 20 mM Tris HCl, pH 7.5, 5 mM
magnesium acetate, 50 µM CaCl2, 20 µM ATP (0.5 µC
32P-ATP/assay), 25 µM myelin basic protein4–14 with
1–2 µg sample protein. Phosphatidylserine (100 µg)
and 10 µg diolein were included in assays of superna-
tant only. Blanks contained no myelin basic protein4–14,
which gave values comparable in value to those ob-
tained when 1 µM protein kinase C inhibitor peptide
was included in the assay. Samples were incubated for 4
min at 30°C. The reaction was stopped by spotting a 30
µl aliquot of the mixture onto a piece of P-81 paper
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(Whatman, Maidstone, UK) which was immediately
placed in 75 mM H2PO4 and washed four times as
described by Yasuda et al. (1990). All radioactivity was
determined using b-scintillation counting in a Beck-
man LS8100. The PKC activity of the membrane frac-
tion was determined to be the activity of the mem-
branes from the lysed synaptosomal fraction minus
that of the non-lysed synaptosomes to exclude PKC
activity located in adherent postsynaptic densities.
Statistical significance was determined by Student’s
t-test. BCA (Pierce, Rockford, IL) was used to measure
protein.
RESULTS
Phosphorylation of NM in response toAMPH
Experiments investigating the effect ofAMPH onNM
phosphorylationwere conducted in synaptosomes resus-
pended in Ca21-replete KRB as described in our previ-
ous studies (Gnegy et al., 1993). As shown in Figure 1,
incubation of striatal synaptosomes with AMPH elic-
ited an increase in phosphoser41-NM with no change in
total NM. Phosphorylation of NM at the ser41 PKC
substrate site was also demonstrated in response to the
phorbol ester TPA (12-O-tetradecanoylphorbol 13-
acetate) and depolarization by 60mMK1. Phosphoryla-
tion of NM in response to AMPH at ser41 was rapid,
being detected by 30 sec and maximal at 2 min (Fig.
2A,B). After stimulation by AMPH, the phosphate level
was stable until at least 10min. Phosphorylation of NM
at ser41 was maximal at 10 µM AMPH (Table I). The
phosphorylation depended upon AMPH uptake since it
was blocked by 10 µM nomifensine (data not shown).
The effect of AMPH on PKC activity was measured in
striatal synaptosomes. Striatal synaptosomes were in-
cubated with 1 µM AMPH for times of 45 sec to 2 min.
Activation by AMPH was assessed by an increase in
PKC activity in themembranesmade from lysed synap-
tosomes and a decrease in activity in the supernatant.
AMPH incubation increased PKC activity in the mem-
brane fraction by 133 6 7 percent (N 5 9, P , 0.005)
over control while the PKC activity in the supernatant
was decreased to 85 6 3 percent of control (P , 0.005).
Control activities in supernatants and membranes
were 2088 6 422 and 425 6 43 pmol/min/mg protein,
respectively.
Effect of AMPH on phosphorylation
of synapsin I at site 3
We investigated whether AMPH would affect the the
phosphorylation state of synapsin I in striatal synapto-
somes using a state-specific antibody for site 3, the CaM
Kinase II substrate site. We found that synapsin I was
phosphorylated very rapidly when synaptosomes were
resuspended in Ca21-replete KRB. To minimize this
problem, synaptosomes were either resuspended in
Ca21-deficient KRB and Ca21 was added at the start of
the assay. Since addition of Ca21 under these conditions
can lead to rapid entry of Ca21 into the synaptosome
(Bowyer and Weiner, 1990), we performed some experi-
ments where synaptosomes were preincubated in the
presence of Ca21 before AMPH was added (as in Figs.
5A, 6B). In these experiments, synaptosomes were
warmed to 37°C and then preincubated in Ca21-replete
KRB at 37°C for 1 min before addition of AMPH. Either
method gave identical results. As shown in Figure
3A,B, AMPH elicited a time-dependent increase in site
3-phospho-synapsin I in striatal synaptosomes. Phos-
phorylation of synapsin I at site 3 was maximal at 30
sec and declined hereafter. The stimulatory effect of
AMPHwas apparent for at least 2 min but there was no
stimulation at 10 min. The dose-dependent stimulation
of site 3-phospho-synapsin I in response to AMPH was
biphasic, being maximal at the low concentration of 1
nM and decreasing at concentrations over 100 nM (Fig.
4). The increase in immunodetectable site 3-phospho-
synapsin I in response to 1 nM AMPH was blocked
when synaptosomes were preincubated with 10 µM
nomifensine (Fig. 5A,B).
Effect of okadaic acid
Since the effect of AMPH on site 3-phospho-synapsin
I content was maintained at times beyond 30 sec and
Fig. 1. Effect of AMPH, TPA, and 30 mM K1 on the level of
phosphoser41-NM in rat striatal synaptosomes. After preparation,
Percoll-purified synaptosomes were resuspended in Ca21-containing
KRB and incubated for 10 min with 5 or 20 µM AMPH, 250 nM
12-O-tetradecanoylphorbol-13-acetate (TPA) or for 60 sec with 30 mM
K1. The NaCl content of the KRBwas reduced commensurate with the
increase in KCl. Levels of phosphoser41-NM and total NM were
measured as described in Materials and Methods and detected using
alkaline phosphatase-coupled secondary antibody.
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appeared greater at 60 sec than at 30 sec, AMPH
treatment could be inhibiting a phosphatase activity
rather than a directly activating a kinase activity. To
examine this, we determined whether incubation with
AMPH would increase the level of site 3-phospho-
synapsin I in the presence of okadaic acid. Okadaic acid
is an inhibitor of phosphatases 1 and 2A, which can
dephosphorylate synapsin I (Sim et al., 1991).At higher
concentrations, okadaic acid also inhibits phosphatase
2B. As shown in Table II, okadaic acid at 10 µM elicited
a robust increase in content of site 3-phospho-synapsin
I, but AMPH was still able to increase the level of site
3-phospho-synapsin I.
Calcium-dependency of the effect of AMPH
on phosphoser41-NM and site
3-phospho-synapsin I content
AMPH-mediated increases in the level of phos-
phoser41-NM were reduced but not abolished when the
assay was conducted in KRB containing no added Ca21
(Fig. 6A). In incubations in which Ca21 was simply
omitted from the KRB (Fig. 6B), site 3-phospho-
synapsin I was detectable, but at lower levels. There
was no increase in the level of site 3-phospho-synapsin I
by AMPH in the absence of Ca21, however (Fig. 6B).
This was also true at concentrations ofAMPH up to 100
nM (data not shown).
Effect of DA receptor blockers on the ability
of AMPH to increase the content of site
3-phospho-synapsin I
To determine whether the effects of AMPH on site
3-phospho-synapsin I phosphorylation were due to re-
leased DA acting at D1 or D2 dopamine receptors, the
effects of the D1 DA receptor antagonist, SCH23390,
and the D2 dopamine receptor antagonist, sulpiride, on
site 3-phospho-synapsin I phosphorylation were exam-
ined. As shown in Table III, there was a partial inhibi-
tion of AMPH-mediated increases in site 3-phospho-
synapsin I content at all concentrations of SCH23390.
Sulpiride had no effect on the stimulatory effect of 1 nM
AMPH (Table III). We have found no inhibitory effect of
D1 orD2DAantagonists on phosphoser41-NMphosphor-
ylation.
Effect of the PKC inhibitor, Ro31-8220,
on theAMPH-mediated increase in content of
phosphoser41-NM and site 3-phospho-synapsin I
If the AMPH-mediated increase in phosphoser41-NM
is due to an activation of PKC, the AMPH effect should
be blocked by a PKC inhibitor. To test this, and deter-
mine whether PKC activation played a role in AMPH-
mediated synapsin I phosphorylation, synaptosomes
were resuspended in Ca21-deficient KRB and incubated
with the selective PKC inhibitor, Ro31-8220, for 20 min
at 4°C prior to addition of 1 nM or 100 nM AMPH.
Fig. 2. Time dependent effect of AMPH on the level of phos-
phoser41-NM in striatal synaptosomes. Percoll-purified synaptosomes
were incubated at 37°C for the given times in the absence or presence of
1 µM AMPH. A: Immunoblot. Levels of phosphoser41-NM were mea-
sured as described in Materials and Methods and detected using ECL.
B: Synapsomes were incubated in the absence (X) or presence (p) of 1
µM AMPH. Values from immunoblots were quantified in O.D. units by
Gaussian integration using the Hoefer GS365W electrophoresis data
system. Values are the average or mean 6 S.E.M. of from two to five
experiments. For time points of 1, 2, and 5 min, P , 0.05 as compared to
control with noAMPH.
TABLE I. Dose-dependent effect of amphetamine on phosphoser41-NM
content in striatal synaptosomes
Amphetamine concentration Phosphoser41-NM content (O.D.)
Buffer 3,860 6 225
0.1 µM 4,812 6 178*
1.0 µM 5,245 6 271*
10 µM 5,772 6 711*
Rat striatal synaptosomes were resuspended in Ca21-replete KRB and incubated
for 5 min at 37°C in the absence or presence of the given concentrations ofAMPH.
Phosphoser41-NM was determined as described in Materials and Methods.
Results from the ECL detection were analyzed by scanning the bands using a
Hoefer GS365W densitometer and quantified by Gaussian integration. Results
are the mean 6 the S.E.M. from four to six experiments. *P , 0.02 as compared
to buffer control by Student’s t-test.
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Under the conditions used to measure synapsin I
phosphorylation, at 45 sec of incubation, 1 nM AMPH
significantly increased the content of phosphoser41-NM
by 31 6 2.7% (P , 0.007, N 5 3). As shown in Figure 7,
the levels of phosphoser41-NM and site 3-phospho-
synapsin I were increased by both 1 nM and 100 nM
AMPH. Ro31-8220, at 10 µM, had no effect on basal
levels of either phosphoser41-NM or site 3-phospho-
synapsin I. The AMPH-induced increase in the content
of both phosphoser41-NM and site 3-phospho-synapsin
I, however, was completely blocked by the PKC inhibi-
tor, Ro31-8220. The AMPH-induced increase in the
level of site 3-phospho-synapsin I was also blocked by
preincubation with 5 µM of the selective CaM Kinase II
inhibitor, KN-62 (data not shown).
DISCUSSION
We have demonstrated that incubation of striatal
synaptosomes with low concentrations of AMPH leads
to modest but significant increases in phosphoser41-NM
and site 3-phospho-synapsin I. The AMPH-mediated
increases in phosphorylated synapsin I and NM signi-
fies that AMPH can alter phosphorylation-related sec-
Fig. 3. Time dependent effect of 1 nM AMPH on the level of site
3-phospho-synapsin I in striatal synaptosomes. Percoll-purified stria-
tal synaptosomes were incubated at 37°C in the absence or presence of
1 nM AMPH. A: Immunoblot was visualized with 125I-protein A as
described in Materials and Methods. B: Results from immunoblot
were quantified using a Phosphor Imager and densitometry values
were obtained as described in Materials and Methods.
Fig. 4. Dose-dependent effect of AMPH on the level of site 3-phos-
pho-synapsin I in striatal synaptosomes. Percoll-purified synapto-
somes were incubated at for 30 sec at 37°C in the presence of various
concentrations of AMPH. Results from immunoblots were quantified
using a Phosphor Imager and densitometry values were obtained as
described inMaterials andMethods. Results are the mean 6 S.E.M. of
five different experiments.
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ond messenger activities in synaptosomes. This work
corroborates earlier results in which we found that
AMPH increased phosphorylation of NM in rat stria-
tum after acute intraperitoneal injection and in striatal
synaptosomes after incubation (Gnegy et al., 1993;
Iwata et al., 1996). Acute intraperitoneal injection of
either 1 or 2.5 mg/kg AMPH, however, did not increase
the level of site 3-phospho-synapsin I in rat striatum
although the level was increased after repeated, inter-
mittent AMPH (Iwata et al., 1996). The results of this
study show that while AMPH can directly increase the
content of site 3-phospho-synapsin I in synaptosomes,
the effect is transient and occurs at very low doses of
AMPH. Any stimulation would likely have preceeded
the 30-min time point chosen for the acute study (Iwata
Fig. 5. A: Effect of nomifensine on AMPH-mediated increases in
the level of site 3-phospho-synapsin I. Percoll-purified synaptosomes
were resuspended in Ca21-deficient KRB and preincubated with buffer
or 10 µM nomifensine for 10 min at 25°C. The synaptosomes were
warmed to 37°C for 3 min, then preincubated with 1.2 mM CaCl2 for 1
min. Either KRB (K) or AMPH (A, at 1 nM) was added and the
incubation was continued for 45 more sec. Levels of phosphoser41-NM
were measured as described in Materials and Methods and detected
using alkaline phosphatase-labeled secondary antibody.B: Percentage
increase in the level of site 3-phospho-synapsin I by 1 nMAMPH in the
absence and presence of 10 µM nomifensine. Results are given as
percentage increase over control values in the absence of 1 nMAMPH.
Nomifensine alone did not change control values (98 6 5% of no
AMPH control). N 5 4. *Value with nomifensine differed from value
without at P , 0.01 by a Student’s paired t-test.
TABLE II. Effect of AMPH and okadaic acid on the level of site
3-phospho-synapsin I in rat striatal synaptosomes
Incubation addition Site 3-phospho-synapsin I (O.D.)
Buffer 96 6 6
1 nMAMPH 201 6 17
10 µM okadaic acid 992 6 32
Okadaic acid 1AMPH 1,271 6 84*
Synaptosomes were resuspended in Ca21-deficient KRB and preincubated in the
absence or presence of 10 µM okadaic acid at 4°C for 20 min. Following
preincubation, Ca21-replete KRB or 1 nM AMPH with Ca21 was added to
synaptosomes for a further 2 min incubation. Site 3-phospho-synapsin I immuno-
reactivity was determined as described in Materials and Methods. Immunoreac-
tivity visualized with 125I-protein A was quantified by a Phosphor Imager and
densitometry values were obtained. *P , 0.04 as compared to value for okadaic
acid alone, N 5 3.
Fig. 6. Calcium dependence of AMPH-mediated increases in levels
of phosphoser41-NM and site 3-phospho-synapsin I. A: Effect of AMPH
on levels of phosphoser41-NM in synaptosomes incubated in Ca21-
deficient (no added calcium, 2Ca21) KRB or Ca21-replete (1.2 mM
CaCl2, 1Ca21)-KRB. Synaptosomes were incubated for 5 min at 37°C
with 10 µM AMPH (A) or with KRB (K). Levels of phosphoser41-NM
were measured as described in Materials and Methods and detected
using ECL. B: Effect of AMPH on levels of site 3-phospho-synapsin I.
Synaptosomes were incubated for 3 min at 37°C in Ca21-deficient (no
added calcium, 2Ca21) or Ca21-replete (1.2 mM CaCl2, 1Ca21)-KRB.
CaCl2 was added to the 1Ca21 samples for one min before addition of
AMPH (A) or KRB (K) to all samples. Samples were incubated with 1
nM AMPH for 45 sec. The immunoblot was visualized using an
alkaline phosphatase-conjugated secondary antibody.
TABLE III. Effect of dopamine antagonists on the AMPH-mediated




Percent of control (%)
SCH23390 Sulpiride
0 0 100 100
1 0 167 6 1.1* 137 6 7**
1 0.1 129 6 13 127 6 20
1 1 132 6 1.7 137 6 14
Percoll-purified synaptosomes were resuspended in Ca21-deficient KRB and
preincubated with the given doses of SCH23390 or sulpiride for 30–60min at 4°C.
Following preincubation, incubations were conducted with Ca21-replete KRB in
the presence or absence of 1 nM AMPH for 30–60 sec. Site 3-phospho-synapsin I
immunoreactivity was determined as described in Materials and Methods.
Immunoreactivity visualized with 125I-protein A was quantified by a Phosphor
Imager and densitometry values were obtained as described in Materials and
Methods. The control value is the value in the absence of AMPH, whether in the
presence or absence of drug. Control values did not change in the presence of
either SCH23390 or sulpiride. *ANOVA for SCH23390 group, P , 0.005, in
Tukey-Kramer multiple comparisons post-test, AMPH alone significantly differ-
ent from any SCH23390-containing sample at P, 0.01 and significantly different
from 100% at P , 0.0001 by Student’s t-test. **ANOVA for sulpiride group is n.s.
Value for AMPH alone is significantly different from 100% at P , 0.05 by
Student’s t-test.
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et al., 1996). In addition, the concentration of AMPH in
the striatum 30 min after a 1 mg/kg intravenous
injection of AMPH is approximately 10 µM (Melega et
al., 1995), suggesting that site 3-phosphosynapsin I
levels at that time could be reduced due to the high
level of AMPH.
Our results suggest that AMPH can increase PKC
activity in synaptosomes as shown by the AMPH-
mediated increase in phosphorylation of a specific PKC
substrate site in NM and by the direct stimulating
effect of AMPH on PKC activation in striatal synapto-
somes. Our results support those of Giambalvo (1992b)
who found that AMPH increased PKC activity in rat
striatal synaptoneurosomes (a 6,000g particulate frac-
tion) and in rat striatum when given in vivo by altering
the Km for calcium (Giambalvo, 1992a). In addition,
drugs that inhibited PKC inhibited AMPH-induced
release of DA (Giambalvo, 1992b). Little is known about
the action of AMPH in synaptosomes and it is unclear
howAMPHwould lead to PKC activation.An alteration
in levels of calcium or of a lipid, such as diacylglycerol
or arachidonic acid, could activate PKC. Although
calcium is not required for AMPH uptake through the
carrier for DA release, AMPH could have an effect on
increasing calcium in the synaptosome. AMPH at con-
centrations from 1 nM to 100 nM elicited an activation
of an inward calcium current in internally perfused
neurons of the snail (Vislobokov et al., 1993). Depletion
of DA from a specific pool in the synaptosome, elicited
by DA release, might have an activating effect on a
signal transduction system.
AMPH could be releasing a substance that is increas-
ing PKC activity. Possibilities include dopamine, other
monoamines such as norepinephrine and serotonin,
glutamate, or even neuropeptides. AMPH-mediated
release of some substances in rat striatum, such as
glutamate (Mora and Porras, 1993), is mediated by
released DA. Our studies with DA antagonists suggest
that DAmay not mediating the increases in synapsin or
NM phosphorylation, although there was some effect of
the D1 antagonist SCH23390 on synapsin I phosphory-
lation. DA has been shown to increase synapsin I
phosphorylation in striatal slices but this effect was
independent of extracellular Ca21 and cAMP mediated
(Walaas et al., 1989) which would likely be reflected at
site 1 on synapsin, a substrate site for protein kinaseA.
It is uncertain whetherAMPH releases DA from synap-
tosomes at concentrations of 1 and 10 nM. Inhibition of
[3H]DA release from striatal synaptoneurosomes by 1
and 10 nM AMPH has been reported (Giambalvo,
1992b) although Raiteri (1976) reported measurable
[3H]DA release in response to 10 nM AMPH in striatal
synaptosomes. An action of released DA at presynaptic
autoreceptors, however, could explain the biphasic na-
ture of the dose response curve for phosphorylation of
synapsin I. Activation of a presynaptic autoreceptor by
DA released at higher doses of AMPH may limit cal-
cium entry into the synaptosome which could account
for the decrease in phosphorylation of synapsin I at $1
µM AMPH. Since AMPH-mediated NM phosphoryla-
tion was much sensitive to calcium, it would be less
affected by presynaptic DA receptor activation. That
could explain the discrepancy between dose response
curves for the AMPH effect on NM vs. synapsin I
phosphorylation.
The data obtained using the PKC inhibitor Ro31-
8220 are consistent with a mechanism whereby stimu-
lation of PKC results in activation of CaM Kinase II
which would lead to a phosphorylation of synapsin I at
site 3. Similar results have been reported previously
(Browning and Dudek, 1992; Ueno and Rosenberg,
1995). Browning and Dudek (1992) found that activa-
tion of PKC increased the phosphorylation of synapsin I
at CaMKinase II substrate sites in the rat hippocampal
slice. Since purified synapsin I could not be directly
phosphorylated by PKC (Browning and Dudek, 1992),
Fig. 7. Effect of the selective protein kinase C inhibitor, Ro31-8220, on the AMPH-mediated increase
in the level of phosphoser41-NM and site 3-phospho-synapsin I. Percoll-purified rat striatal synaptosomes
were preincubated with Ca21-deficient KRB or 10 µM Ro31-8220 for 20 min at 4°C. Either KRB or the
indicated AMPH was then added with Ca21 to give a final [Ca21] of 1.2 mM and the incubation proceeded
for 1 min at 37°C. Immunoreactivity visualized with 125I-proteinA.
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this activation was likely due to cross-talk between
PKC and CaM Kinase II. Similarly, Ueno and Rosen-
berg (1995) reported that phorbol ester stimulation of
PKC led to phosphorylation of the myristoylated ala-
nine-rich C-kinase substrate (MARCKS), NM, and syn-
apsin I in rat cerebral cortical synaptosomes. CaM itself
may play a role since a PKC-mediated dissociation of
CaM fromNM orMARCKSwould activate CaMKinase
II. The ability of AMPH to extend the time course of
phosphorylation of synapsin I at site 3 could be due to a
release of CaM providing longer activation of CaM
Kinase II. This mechanism has been demonstrated in
PC12 cells (MacNicol and Schulman, 1992). Although
the dose response curves for AMPH in stimulating
synapsin I and NM phosphorylation appeared quite
different, low concentrations of AMPH could increase
NM phosphorylation when phosphoser41-NM was mea-
sured under the conditions used for synapsin I phosphor-
ylation. Possibly the influx of Ca21 upon addition of
Ca21 to synaptosomes in Ca21-deficient KRB (Bowyer
and Weiner, 1990) is synergistic with AMPH, providing
enhanced activation of PKC and a Ca21- and PKC-
mediated dissociation of CaM from NM which would
increase NM phosphorylation (Alexander et al., 1987).
Release of CaM from NM or MARCKS could lead to
increased activation of the plasma membrane Ca21
pump removing Ca21 from the synaptosome and de-
creasing CaMKinase II activation.Asmentioned above,
an action of released DA in limiting Ca21 influx into the
synaptosome could also help explain the difference.
It is unclear whether the phosphorylations or cross-
talk occur in the same population of synaptosomes or
whether these events even occur in dopaminergic synap-
tosomes. The mRNA for NM co-localizes with mRNA for
tyrosine hydroxylase in rat brainstem and disappears
after 6-hydroxydopamine treatment (Bendotti et al.,
1991). On the other hand, localization of NM is not
selective for nigrostriatal terminals in the striatum
since nigral 6-hydroxydopamine lesions decreases the
striatal NM content by only 20%, a figure commensu-
rate with the estimated number of dopaminergic termi-
nals in the striatum (S. Iwata, preliminary data).
Synapsin I is present in virtually all neurons, primarily
in small synaptic vesicles responsible for storage and
release of classical transmitters (Greengard et al.,
1994). Small, clear vesicles and synapsin I are promi-
nent in glutamatergic synaptosomes (Verhage et al.,
1994). There appear to be interactions between dopa-
minergic and glutamatergic nerve terminals in stria-
tum in that glutamate and DA may alter each other’s
release (Maura et al., 1988; Mora and Porras, 1993; and
see references in Finnegan and Taraska, 1996). Low
concentrations of DA suppressed the K1-induced re-
lease of glutamate in a presynaptic-inhibitory manner
through dopamineD2 receptors on glutaminergic termi-
nals innervated from cerebral cortex (Maura et al.,
1988). If low concentrations of AMPH do decrease DA
release (Giambalvo, 1992b), a decrease in DA release
could activate the glutamatergic synaptosomes result-
ing in enhanced phosphorylation of synapsin I at site 3.
The phosphorylation of synapsin I at site 3 by AMPH
in synaptosomes is unlikely to be related to the immedi-
ate effect of AMPH in releasing DA since synapsin I
phosphorylation at site 3 is so strongly calcium-
dependent and AMPH-mediated DA release is calcium-
independent. On the other hand, there are data suggest-
ing that DA release by AMPH is dependent upon
continued synthesis of cytoplasmic pools of DA (Chiueh
and Moore, 1975). Low concentrations of AMPH (#1
µM) increase DA synthesis in striatal synaptosomes
(Kuczenski, 1975; Roberts and Patrick, 1979; Uretsky
and Snodgrass, 1977). The magnitude of the AMPH
effect on DA synthesis is comparable to the magnitude
of AMPH-induced increases in levels of phosphorylated
proteins in this report. Moreover, the effect of AMPH on
DA synthesis is biphasic, with inhibition occurring at
concentrations over 1 µM AMPH (Kuczenski, 1975;
Roberts and Patrick, 1979; Uretsky and Snodgrass,
1977). Increased DA synthesis by AMPH is calcium-
dependent (Schwarz et al., 1980) and occurs at doses of
AMPH an order of magnitude less than those eliciting
DA release (Kuczenski, 1975). Evidence suggests that
depolarization and AMPH stimulate DA synthesis by
similar calcium-dependent mechanisms (Roberts and
Patrick, 1979; Uretsky and Snodgrass, 1977). Depolar-
ization of synaptosomes leads to a Ca21-dependent
phosphorglation of tyrosine hydroxylase through phos-
phorylation of a CaM Kinase II-substrate site in the
enzyme (Haycock and Haycock, 1991; Waymire and
Craviso, 1993). A calcium-dependent increase in DA
synthesis in response to AMPH has been reported in
vivo (Fung and Uretsky, 1982). Therefore it is possible
that AMPH treatment results in an activation of CaM
Kinase II which could phosphorylate several sub-
strates, including synapsin I and potentially tyrosine
hydroxylase.AnAMPH-mediated increase in PKCactiv-
itymay also contribute to activation of tyrosine hydroxy-
lase since protein kinase C can phosphorylate and
activate tyrosine hydroxylase (Albert et al., 1984; Hay-
cock and Haycock, 1991). Calcium-dependent effects of
AMPH on behavior have also been demonstrated. Intra-
striatal administration of EGTA blocked AMPH-in-
duced circling behavior in unilateral 6-hydroxydopa-
mine lesioned mice and the EGTA effect was reversed
with calcium (Fung and Uretsky, 1980). There was no
effect on apomorphine-induced circling suggesting a
presynaptic mechanism. Therefore, the calcium-depen-
dent effects of AMPH could be important both for DA
synthesis, a behavioral component, and other unknown
second messenger activities.
In summary, we have demonstrated that incubation
of striatal synaptosomes with AMPH can lead to in-
creases in the level of phosphate incorporated into NM
at ser41, the PKC substrate site, and of synapsin I at
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site 3, the CaM Kinase II substrate site. These results
indicate that AMPH can have effects on phosphoryla-
tion-related second messenger activity within the syn-
aptosome and that AMPH can affect second messenger
function in both a Ca21-dependent and a Ca21-indepen-
dent fashion.
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